# NIH Awards Gene Therapy Grant to Inomagen

The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), awarded a **$2.9 million Small Business Innovation Research (SBIR) grant** to Inomagen Therapeutics Inc. on September 17, 2026. This funding supports the preclinical development and manufacturing of a plasmid-based gene therapy targeting atrial fibrillation (AFib), aiming to provide a novel, non-ablative treatment alternative to existing therapies. The grant facilitates progress toward an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), highlighting a significant opportunity for contractors specializing in gene therapy research, biomanufacturing, and regulatory support.

- **Why this matters:** This grant signals NIH's commitment to advancing innovative cardiac gene therapies, creating procurement opportunities in specialized biotech development and manufacturing sectors.
- Contractors with expertise in plasmid manufacturing, preclinical testing, and regulatory consulting may find new business prospects supporting Inomagen's development pipeline.
- Procurement professionals should note the involvement of federal agencies NIH, NHLBI, and FDA, indicating potential future contracts or collaborations in gene therapy and cardiovascular treatment innovation.
- Organizations can leverage this development to align with emerging federal priorities in precision medicine and gene therapy commercialization.

**Jurisdictions:** federal
**Industries:** Healthcare, Information Technology
**Topics:** Grants & Funding, Regulatory Compliance
**Published:** September 17, 2026

### Government Entities
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health (NIH)
- U.S. Food and Drug Administration (FDA)

### Vendors
- Inomagen Therapeutics Inc. (awardee)

### Sources
- [NIH grant supports Inomagen’s gene therapy for atrial fibrillation | BioWorld](https://www.bioworld.com/articles/734120-nih-grant-supports-inomagens-gene-therapy-for-atrial-fibrillation) - BioWorld News
- [Biotech company receives second grant to develop gene therapy for AFib](https://cardiovascularbusiness.com/topics/cardiac-imaging/ep-lab/biotech-company-receives-second-grant-develop-gene-therapy-afib) - Cardiovascular Business